Company / Operating Cash Flow
Revolution Medicines, Inc. Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$897.7M
FY2025
5-year range
-$897.7M / -$49.6M
FY2021-FY2025
Trend
-61.0%
vs FY2024
Sector context
#214 of 216
Health Care
What the data says
Among 216 Health Care companies, Revolution Medicines, Inc. is in the bottom 1% for operating cash flow. Operating Cash Flow has declined for 5 consecutive years, from $1M in FY2020 to -$898M in FY2025.
Based on SEC 10-K filings.
-$898M in FY2025.
Declined from -$351M to -$898M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 216This company -$897.7M Sector average $659.0M
▼
-236.2% below sector average
Key checks
Key Insights
- Revolution Medicines, Inc.'s operating cash flow has declined for 5 consecutive years.
- In FY2025, operating cash flow decreased 61.0% year-over-year.
- Ranks #214 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$897.7M | -61.0% |
| FY2024 | -$557.4M | -59.0% |
| FY2023 | -$350.6M | -250.3% |
| FY2022 | -$100.1M | -101.7% |
| FY2021 | -$49.6M | -4190.4% |
| FY2020 | $1.2M | +102.4% |
| FY2019 | -$49.6M | -4190.4% |
| FY2018 | $1.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026